Skip to main content

Table 1 League table of pain freedom at 2 h

From: Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis

DFN-02

          

2.67 (0.98,7.30)

0.70 (0.19,2.60)

Ket

   

1.19 (0.50,2.86)

     

3.34 (1.25,8.87)

0.88 (0.27,2.91)

1.25 (0.44,3.54)

AVP-825

        

3.03(1.63,5.62)

1.35 (0.31,5.88)

1.91 (0.49,7.40)

1.52 (0.44,5.28)

ROX-828

       

1.99 (0.66,5.83)

1.41 (0.45,4.36)

2.00 (0.83,4.83)

1.59 (0.71,3.56)

1.04 (0.32,3.41)

Suma10mg

0.52 (0.34,0.79)

     

1.82 (1.19,3.14)

0.77 (0.26,2.32)

1.10 (0.49,2.45)

0.87 (0.41,1.87)

0.57 (0.18,1.81)

0.55 (0.36,0.83)

Suma20mg

     

3.48 (2.26,5.33)

0.86 (0.28,2.67)

1.23 (0.47,3.22)

0.98 (0.44,2.17)

0.64 (0.20,2.09)

0.61 (0.30,1.24)

1.12 (0.58,2.16)

Zol2.5 mg

*0.59 (0.37,0.94)

   

3.06 (1.74,5.59)

0.57 (0.20,1.65)

0.82 (0.34,1.97)

0.65 (0.32,1.30)

0.43 (0.14,1.30)

0.41 (0.23,0.74)

0.74 (0.44,1.26)

a0.66 (0.42,1.05)

Zol5mg

   

4.66 (3.43,6.35)

1.59 (0.54,4.65)

2.26 (0.92,5.56)

1.80 (0.87,3.71)

1.18 (0.38,3.65)

1.13 (0.61,2.09)

2.06 (1.18,3.60)

1.84 (1.01,3.40)

2.77 (1.73,4.44)

Zave

  

1.68 (1.18,2.41)

0.73 (0.23,2.29)

1.03 (0.39,2.77)

0.82 (0.36,1.88)

0.54 (0.16,1.79)

b0.52 (0.25,1.08)

0.94 (0.47,1.87)

0.84 (0.41,1.74)

1.27 (0.69,2.34)

0.46 (0.24,0.87)

MAP0004

 

3.67 (2.18,3.20)

0.73 (0.17,3.22)

1.04 (0.27,4.06)

0.83 (0.24,2.90)

0.54 (0.12,2.49)

0.52 (0.16,1.72)

0.95 (0.29,3.04)

0.84 (0.26,2.79)

1.27 (0.41,3.93)

0.46 (0.15,1.44)

1.00 (0.30,3.37)

Buto

3.67(1.25,10.7)

b2.68 (0.97,7.38)

3.81 (1.67,8.70)

3.03 (1.62,5.69)

1.99 (0.68,5.81)

1.91 (1.15,3.15)

3.48 (2.27,5.33)

3.10 (1.89,5.10)

4.67 (3.43,6.34)

1.68 (1.18,2.41)

3.69 (2.15,6.31)

3.67 (1.24,10.87)

Placebo

  1. Pairwise (upper-right portion) and network (lower-left portion) meta-analysis results are presented as estimated effect sizes for pain freedom at 2 h. For the result, outcomes are expressed as odds ratios (OR) with 95% credible interval (CI) (OR of > 1 indicated that the treatment specified in the row got more improvement than that specified in the column), 0 < OR < 1, the opposite. For the network meta-analysis, OR of > 1 indicated that the treatment specified in the column got better improvement than that specified in the row, 0 < OR < 1, the opposite. 95% CI that did not contain one was considered to have a statistical difference
  2. Bold results indicated statistical significance. Marked with aindicated a significant difference between direct and mixed comparisons. bindicated a significant difference between the basic model and sensitivity analysis
  3. DFN-02, sumatriptan nose spray 10 mg with a permeation enhancer; Ket, ketorolac nose spray 31.5 mg; Suma10mg, sumatriptan nose spray 10 mg; Suma20mg, sumatriptan nose spray 20 mg; Zol2.5 mg, zolmitriptan nose spray 2.5 mg; Zol5mg, zolmitriptan nose spray 5 mg; Zave, zavegepant nose spray 10 mg; Buto, butorphanol nose spray 1 mg; AVP-825, a drug-device combination of 22 mg sumatriptan powder; MAP0004, a dihydroergotamine inhaler; ROX-828, ketorolac 31.5 mg with 6% of lidocaine; DHE, dihydroergotamine nose spray 2 mg
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us